Unicycive Therapeutics, Inc. (Nasdaq: UNCY) is a biotechnology company accelerating healthcare innovation in overlooked areas to address the unmet needs of patients. Our world-class team has a proven track record of advancing drug candidates through all stages — from development to NDA submission, approval, and to successful commercial launch.

Unicycive’s lead investigational treatment is oxylanthanum carbonate (OLC), a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury

Unicycive is selectively seeking in-licensing opportunities that complement our current pipeline and leverage our team’s significant experience in nephrology, autoimmune, metabolic, and oncology therapeutic areas. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.